Loading...
•
Jun 30, 2022
Y-mAbs Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022.
Key Takeaways
Y-mAbs reported net revenues of $10.8 million. The highlight of the second quarter was FDA acceptance of their BLA filing for omburtamab. They had approximately $133.7 million in cash and cash equivalents as of June 30, 2022, and they continue to expect full year 2022 cash burn of $78-83 million.
FDA accepted BLA filing for omburtamab.
Phase 2 naxitamab chemo-immunotherapy trial met primary endpoints.
Net revenues were $10.8 million for the quarter.
Cash and cash equivalents were $133.7 million as of June 30, 2022.
Y-mAbs
Y-mAbs
Forward Guidance
Management reiterates all elements of its financial guidance including: The revenue guidance includes an incremental benefit from international revenues.